Pro-Dex Colo (PDEX) Stock News

Pro-Dex (NasdaqCM: PDEX) completed the acquisition of Advanced Precision Machining LLC (APM) on February 9, 2026. APM is a Costa Mesa manufacturing facility producing machined sub-assemblies and aerospace/defense parts, and holds ITAR and JCP registrations.

The company said APM will operate independently and that the length of APM's accounting close may shift consolidated reporting timing closer to SEC deadlines. Management cited a contract extension with its largest customer and expects revenue growth and potential manufacturing efficiencies from APM's automation.

Pro-Dex (NasdaqCM: PDEX) reported fiscal 2026 Q2 results for the quarter ended December 31, 2025, with net sales of $18.7M (up 11% YoY) and net income of $2.2M ($0.66 diluted). Six-month sales rose 17% to $37.2M and six-month net income was $6.9M ($2.07 diluted), which included a $6.8M realized gain partially offset by a $3.2M reversal of prior unrealized gains. Management noted a three-year contract extension with its largest customer and a planned acquisition of a local machine shop to secure capacity.

Pro-Dex (NasdaqCM: PDEX) announced a contract amendment with its largest customer executed on December 17, 2025 that extends an agreement scheduled to terminate on December 31, 2025 through December 31, 2028. The amendment includes minimum purchase volumes for 2026 and 2027, and continues a commercial relationship that will total more than fifteen years.

The company makes autoclavable, battery-powered and electric surgical drivers and shavers, licensed torque-limiting software, and sells rotary air motors (described as a de minimis portion of revenue). Management framed the amendment as positioning Pro-Dex for continued revenue growth.

Pro-Dex (Nasdaq: PDEX) reported fiscal 2026 first quarter results for the period ended September 30, 2025. Net sales rose 24% to $18.5M, driven mainly by resumption of shipments of a next-generation handpiece to the company's largest customer. Gross margin fell 6 percentage points to 29% due to higher costs and tariffs. Operating income was $3.1M and net income was $4.68M ($1.40 diluted), which included $3.3M of unrealized investment gains. The company received $8.9M cash from the sale of Monogram shares and filed its Form 10-Q on October 30, 2025.

Pro-Dex (NasdaqCM: PDEX) issued a market clarification on October 16, 2025 to help avoid confusion between its Nasdaq-listed common stock and an unrelated crypto entity using the PDEX symbol. The company emphasized there is no relationship or affiliation with Polkadex and urged investors to verify whether research or trades referencing PDEX relate to Pro-Dex or to Polkadex.

Pro-Dex designs and manufactures autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and sells rotary air motors that represent a de minimis portion of revenue. Contact: Richard L. Van Kirk, CEO, (949) 769-3200.

Pro-Dex (NASDAQ:PDEX), a manufacturer of surgical drivers and shavers, reported its fiscal 2025 Q4 and full-year results. Annual net sales increased 24% to $66.6 million, driven by next-generation handpiece sales to their largest customer. Full-year net income surged to $9.0 million ($2.67 per diluted share), up from $2.1 million ($0.60 per diluted share) in fiscal 2024.

Q4 net sales grew 16% to $17.5 million, though gross margin declined from 27% to 20% due to unfavorable product mix and tariff costs. The company reported a strong backlog of $50.4 million as of June 30, 2025, and management expects continued revenue and operating income growth in fiscal 2026.

Pro-Dex (PDEX) reported strong financial results for Q3 FY2025. Net sales increased 22% to $17.4 million, driven by $6.2 million in shipments of their largest customer's next-generation orthopedic handpiece. Gross profit rose 45% to $5.8 million due to favorable product mix. Operating income grew 65% to $3.6 million, while net income surged to $3.3 million ($0.98 per diluted share) from $655,000 ($0.19 per diluted share) year-over-year. For the nine-month period, net sales increased 27% to $49.1 million, with net income reaching $7.8 million ($2.31 per diluted share). The company is on track for a record revenue year, benefiting from strong demand for its surgical devices and improved operational efficiency.

Pro-Dex (PDEX) reported strong financial results for Q2 FY2025. Net sales increased 33% to $16.8 million, driven by $3.1 million in shipments of next-generation orthopedic handpieces and $1.6 million increase in repair revenue from their largest customer.

Gross profit rose 81% to $5.1 million, with gross margin improving by 8 percentage points to 30%. Operating income surged 247% to $2.7 million, while net income reached $2.0 million ($0.61 per diluted share), up from $500,000 ($0.14 per diluted share) in Q2 FY2024.

For the six-month period, net sales grew 29% to $31.7 million, with net income of $4.5 million ($1.33 per diluted share), compared to a net loss of $115,000 in the prior year period. The company expects continued revenue growth in Q3 and Q4 due to ongoing production shipments of the next-generation handpiece.

Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q1 FY2025. Net sales increased 25% to $14.9 million, driven by increased repairs and shipment of next-generation handpiece. Gross profit rose 41% with margin expanding to 35%. Operating income grew 64% to $3.0 million. Net income improved to $2.5 million ($0.75 per diluted share) from a net loss of $615,000 in the prior year. The company expects to ship production volumes of the new handpiece during second half of fiscal year.